HF
MTNB icon

HRT Financial’s Matinas BioPharma MTNB Stock Holding History

HRT Financial’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,784
Closed -$20K – 3720
2025
Q3 		$20K Buy
+10,784
New +$15.5K ﹤0.01% 2702
2023
Q3 		– Sell
-205
Closed -$3K – 2843
2023
Q2 		$3K Buy
+205
New +$4.78K ﹤0.01% 2265
2023
Q1 		– Sell
-1,091
Closed -$27K – 2939
2022
Q4 		$27K Buy
1,091
+831
+320% +$27.6K ﹤0.01% 2153
2022
Q3 		$8K Buy
+260
New +$10.2K ﹤0.01% 2552
2021
Q2 		– Sell
-14,874
Closed -$780K – 3276
2021
Q1 		$780K Buy
+14,874
New +$998K 0.01% 1374
2020
Q2 		– Sell
-1,463
Closed -$43K – 1684
2020
Q1 		$43K Buy
+1,463
New +$88.3K ﹤0.01% 648

Other funds holding MTNB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial's MTNB Position: Q4 2025 in Review

HRT Financial sold out of Matinas BioPharma (MTNB) in Q4 2025, closing a stake of 10,784 shares — an estimated $20K sold.

HRT Financial first reported a position in MTNB in Q1 2020 and held it in 6 quarters. The position peaked at $780K in Q1 2021. 30 funds tracked by Wall St. Rank hold MTNB as of Q4 2025.

  • HRT Financial reported no remaining Matinas BioPharma position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 10,784 Matinas BioPharma shares in Q4 2025, an estimated $20K.
  • HRT Financial first reported a position in Matinas BioPharma in Q1 2020 and held it in 6 quarters.
  • HRT Financial's Matinas BioPharma position peaked at $780K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.